ISCO
What one share of International Stem Cell holds
Pharmaceutical Preparations
International Stem Cell Corporation (sometimes referred to herein as “ISCO”, the “Company”, “we”, “us”, or “our”) is a clinical stage biotechnology company focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities and two revenue-generating businesses offering potential for increased future revenue.
International Stem Cell’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.19 |
|---|---|
| Profit | −$0.07 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.04 |
| Cash and investments | $0.14 |
| Book value | −$0.53 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.25 | −$0.34 | $0.07 | −$1.39 | — | $0.87 |
| 2017 | $1.79 | −$1.46 | $0.03 | −$0.54 | — | $0.34 |
| 2018 | $1.74 | −$0.33 | $0.03 | −$0.20 | — | $0.37 |
| 2019 | $1.26 | −$0.57 | $0.02 | −$0.21 | — | −$0.38 |
| 2020 | $0.95 | −$0.36 | $0.00 | −$0.05 | — | −$0.57 |
| 2021 | $0.92 | −$0.11 | $0.00 | −$0.17 | — | −$0.57 |
| 2022 | $1.02 | −$0.04 | $0.00 | $0.04 | — | −$0.56 |
| 2023 | $0.97 | −$0.02 | $0.01 | $0.11 | — | −$0.52 |
| 2024 | $1.14 | −$0.03 | $0.02 | −$0.02 | — | −$0.49 |
| 2025 | $1.14 | −$0.05 | $0.01 | −$0.00 | — | −$0.51 |